Dobutamine

Dobutamine is a synthetic catecholamine primarily used as an inodilator in ICU practice.

1. Pharmacology & Receptor Profile

Mechanism of Action

  • β1-adrenergic agonist (predominant) myocardial contractility
  • Mild β2 activity peripheral vasodilation
  • Minimal α1 effect (balanced by β2 effect)

Unlike dopamine, it has no significant dopaminergic renal effect.


2. Hemodynamic Effects

Parameter

Effect

Cardiac Output

↑↑

Stroke Volume

↑↑

Heart Rate

Mild

SVR

(mild to moderate)

Pulmonary Vascular Resistance

MAP

Variable (may fall if vasodilatory effect dominates)

Myocardial O2 consumption

 In hypotensive patients, dobutamine may worsen hypotension often combined with norepinephrine.


3. Dose range:

    • 2–5 mcg/kg/min low inotropic effect
    • 5–10 mcg/kg/min standard ICU dose
    • 10–20 mcg/kg/min increased tachyarrhythmia risk

No renal dose adjustment required.


4. Indications in Critical Care

A. Cardiogenic Shock (Most Important)

Used in:

  • Acute MI with low cardiac output
  • Decompensated heart failure
  • Post-cardiotomy low-output state
  • Myocarditis

Guideline Position

  • ESC Cardiogenic Shock guidelines: Dobutamine preferred in low-output state with adequate MAP.
  • Surviving Sepsis Campaign: Add dobutamine if:
    • Persistent hypoperfusion despite fluids + norepinephrine
    • Myocardial dysfunction with low cardiac output


B. Septic Shock with Myocardial Dysfunction

When:

  • Low ScvO₂ despite adequate MAP
  • Echo shows depressed LV function

Used as add-on to norepinephrine, not monotherapy.


C. Right Ventricular Failure

Useful in:

  • RV infarction
  • Pulmonary hypertension with low output
  • Massive PE (careful use)

Because:

  • Improves contractility
  • Reduces PVR (via β2 effect)


D. Stress Echocardiography

Pharmacologic stress testing agent (non-ICU indication).


5. Comparison with Other Inotropes

Drug

Inotropy

Vasodilation

Best Use

Dobutamine

Strong

Mild

Cardiogenic shock

Dopamine

Moderate

Dose-dependent

Bradycardia + shock

Milrinone

Strong

Strong

Pulmonary HTN, RV failure

Epinephrine

Strong

Variable

Refractory shock

6. Adverse Effects

  • Tachycardia
  • Atrial fibrillation
  • Ventricular arrhythmias
  • Hypotension (vasodilatory effect)
  • Myocardial ischemia
  • Tolerance after 48–72 hrs (β-receptor downregulation)

 Avoid in:

  • Hypertrophic obstructive cardiomyopathy (increases LVOT obstruction)
  • Uncontrolled arrhythmias


7. Hemodynamic Monitoring in ICU

Should be guided by:

  • Echo (LV/RV function)
  • Cardiac output monitoring (PiCCO, PAC, FloTrac)
  • Lactate trends
  • ScvO₂
  • Urine output

Target:
CI > 2.2 L/min/m²
Improving lactate
End-organ perfusion


8. Dobutamine vs Milrinone 

Feature

Dobutamine

Milrinone

Mechanism

β1 agonist

PDE-3 inhibitor

Renal adjustment

No

Yes

Onset

Rapid

Slower

Hypotension risk

Moderate

High

Best in

Acute shock

Chronic HF, RV failure

Arrhythmias

Common

Less than dobutamine